X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA JUBILANT LIFE SCIENCES ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 118.3 19.2 617.4% View Chart
P/BV x 16.8 3.9 428.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,285187 687.9%   
Low Rs63465 973.9%   
Sales per share (Unadj.) Rs189.6364.3 52.0%  
Earnings per share (Unadj.) Rs-0.26.8 -3.0%  
Cash flow per share (Unadj.) Rs3.824.5 15.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs68.6164.9 41.6%  
Shares outstanding (eoy) m25.00159.28 15.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,464.0%   
Avg P/E ratio x-4,712.718.4 -25,615.0%  
P/CF ratio (eoy) x249.65.1 4,854.6%  
Price / Book Value ratio x14.00.8 1,830.2%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m23,98820,061 119.6%   
No. of employees `0001.66.2 25.2%   
Total wages/salary Rs m1,60511,052 14.5%   
Avg. sales/employee Rs Th3,040.29,383.0 32.4%   
Avg. wages/employee Rs Th1,029.21,786.9 57.6%   
Avg. net profit/employee Rs Th-3.3176.3 -1.9%   
INCOME DATA
Net Sales Rs m4,74058,034 8.2%  
Other income Rs m92191 48.3%   
Total revenues Rs m4,83258,224 8.3%   
Gross profit Rs m-1305,786 -2.2%  
Depreciation Rs m1012,812 3.6%   
Interest Rs m03,237 0.0%   
Profit before tax Rs m-139-72 192.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1392,145 6.5%   
Tax Rs m5696 0.7%   
Profit after tax Rs m-51,090 -0.5%  
Gross profit margin %-2.710.0 -27.5%  
Effective tax rate %-3.7-965.9 0.4%   
Net profit margin %-0.11.9 -5.7%  
BALANCE SHEET DATA
Current assets Rs m2,72629,280 9.3%   
Current liabilities Rs m2,43538,912 6.3%   
Net working cap to sales %6.1-16.6 -37.0%  
Current ratio x1.10.8 148.8%  
Inventory Days Days7484 87.4%  
Debtors Days Days4151 80.4%  
Net fixed assets Rs m1,03555,712 1.9%   
Share capital Rs m50155 32.4%   
"Free" reserves Rs m94220,968 4.5%   
Net worth Rs m1,71626,265 6.5%   
Long term debt Rs m017,169 0.0%   
Total assets Rs m4,15688,606 4.7%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.7 0.0%  
Sales to assets ratio x1.10.7 174.1%   
Return on assets %-0.14.9 -2.5%  
Return on equity %-0.34.2 -7.1%  
Return on capital %011.6 0.0%  
Exports to sales %5.737.8 15.1%   
Imports to sales %6.516.5 39.2%   
Exports (fob) Rs m27021,933 1.2%   
Imports (cif) Rs m3069,567 3.2%   
Fx inflow Rs m37522,004 1.7%   
Fx outflow Rs m47011,749 4.0%   
Net fx Rs m-9610,255 -0.9%   
CASH FLOW
From Operations Rs m-88,026 -0.1%  
From Investments Rs m-146-1,744 8.4%  
From Financial Activity Rs m862-4,447 -19.4%  
Net Cashflow Rs m7091,834 38.6%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 0.3 8.7 3.4%  
FIIs % 15.7 21.2 74.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.1 43.1%  
Shareholders   12,856 23,815 54.0%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   MERCK LTD  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull End to the Trading Day; Metal & Auto Stocks Fall(Closing)

Indian share markets continued to trade range-bound in the afternoon session amid mixed international markets. At the closing bell, the BSE Sensex closed higher by 27 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 23, 2017 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS